Logo image of TLRY

TILRAY BRANDS INC (TLRY) Stock Fundamental Analysis

USA - NASDAQ:TLRY - US88688T1007 - Common Stock

1.21 USD
-0.05 (-3.97%)
Last: 9/19/2025, 8:00:01 PM
1.23 USD
+0.02 (+1.65%)
After Hours: 9/19/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TLRY. TLRY was compared to 197 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. TLRY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TLRY has reported negative net income.
In the past year TLRY has reported a negative cash flow from operations.
In the past 5 years TLRY always reported negative net income.
In the past 5 years TLRY reported 4 times negative operating cash flow.
TLRY Yearly Net Income VS EBIT VS OCF VS FCFTLRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500M -1B -1.5B -2B

1.2 Ratios

TLRY has a worse Return On Assets (-105.42%) than 76.53% of its industry peers.
With a Return On Equity value of -144.68%, TLRY is not doing good in the industry: 66.84% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -105.42%
ROE -144.68%
ROIC N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
TLRY Yearly ROA, ROE, ROICTLRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

TLRY has a Gross Margin (29.29%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of TLRY has grown nicely.
TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.37%
GM growth 5YN/A
TLRY Yearly Profit, Operating, Gross MarginsTLRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
TLRY has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TLRY has a worse debt to assets ratio.
TLRY Yearly Shares OutstandingTLRY Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TLRY Yearly Total Debt VS Total AssetsTLRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -1.31, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
TLRY has a Altman-Z score of -1.31. This is comparable to the rest of the industry: TLRY outperforms 47.96% of its industry peers.
TLRY has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.19, TLRY is in line with its industry, outperforming 46.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -1.31
ROIC/WACCN/A
WACC9.09%
TLRY Yearly LT Debt VS Equity VS FCFTLRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 2.46 indicates that TLRY has no problem at all paying its short term obligations.
With a Current ratio value of 2.46, TLRY perfoms like the industry average, outperforming 45.41% of the companies in the same industry.
TLRY has a Quick Ratio of 1.49. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
TLRY's Quick ratio of 1.49 is on the low side compared to the rest of the industry. TLRY is outperformed by 60.71% of its industry peers.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 1.49
TLRY Yearly Current Assets VS Current LiabilitesTLRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

TLRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -490.77%.
TLRY shows a small growth in Revenue. In the last year, the Revenue has grown by 4.11%.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.52% yearly.
EPS 1Y (TTM)-490.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3150%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y9.33%
Revenue growth 5Y37.52%
Sales Q2Q%-2.33%

3.2 Future

TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.55% yearly.
The Revenue is expected to grow by 4.43% on average over the next years.
EPS Next Y92.7%
EPS Next 2Y39.41%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue Next Year3.05%
Revenue Next 2Y3.9%
Revenue Next 3Y4.38%
Revenue Next 5Y4.43%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TLRY Yearly Revenue VS EstimatesTLRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TLRY Yearly EPS VS EstimatesTLRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLRY Price Earnings VS Forward Price EarningsTLRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

78.06% of the companies in the same industry are more expensive than TLRY, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 55.05
TLRY Per share dataTLRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as TLRY's earnings are expected to grow with 26.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.41%
EPS Next 3Y26.96%

More info and screens

0

5. Dividend

5.1 Amount

TLRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

NASDAQ:TLRY (9/19/2025, 8:00:01 PM)

After market: 1.23 +0.02 (+1.65%)

1.21

-0.05 (-3.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-08 2025-10-08/bmo
Inst Owners9.13%
Inst Owner Change10.37%
Ins Owners0.29%
Ins Owner Change3.78%
Market Cap1.35B
Analysts72.5
Price Target1.03 (-14.88%)
Short Float %14.59%
Short Ratio2.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2749.13%
Min EPS beat(2)-5362.97%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-1413.07%
Min EPS beat(4)-5362.97%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-730.51%
EPS beat(12)1
Avg EPS beat(12)-762.79%
EPS beat(16)3
Avg EPS beat(16)-613.4%
Revenue beat(2)0
Avg Revenue beat(2)-10.25%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-7.23%
Revenue beat(4)0
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-4.66%
Revenue beat(8)0
Avg Revenue beat(8)-5.77%
Revenue beat(12)1
Avg Revenue beat(12)-3.94%
Revenue beat(16)1
Avg Revenue beat(16)-4.24%
PT rev (1m)5.79%
PT rev (3m)-20.47%
EPS NQ rev (1m)35.71%
EPS NQ rev (3m)25%
EPS NY rev (1m)40%
EPS NY rev (3m)30%
Revenue NQ rev (1m)-0.78%
Revenue NQ rev (3m)-4.7%
Revenue NY rev (1m)-2.1%
Revenue NY rev (3m)-4.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.65
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 1.83
EV/EBITDA 55.05
EPS(TTM)-1.54
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.73
BVpS1.35
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.42%
ROE -144.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.29%
FCFM N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.37%
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA 11.15
Cap/Depr 24.66%
Cap/Sales 4.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.46
Quick Ratio 1.49
Altman-Z -1.31
F-Score4
WACC9.09%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.02%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-490.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3150%
EPS Next Y92.7%
EPS Next 2Y39.41%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y9.33%
Revenue growth 5Y37.52%
Sales Q2Q%-2.33%
Revenue Next Year3.05%
Revenue Next 2Y3.9%
Revenue Next 3Y4.38%
Revenue Next 5Y4.43%
EBIT growth 1Y-11.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.68%
EBIT Next 3Y29.62%
EBIT Next 5Y17.51%
FCF growth 1Y-111.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-206.1%
OCF growth 3YN/A
OCF growth 5YN/A